-
EP2664334
European procedure
Extract from the Register of European Patents
EP About this file: EP2664334
| EP2664334 - Regimens for intra-articular viscosupplementation [Right-click to bookmark this link] | Status | Opposition rejected Status updated on 10.11.2017 Database last updated on 02.11.2024 | |
| Former | The patent has been granted Status updated on 25.07.2017 | Most recent event Tooltip | 10.11.2017 | Opposition rejected | published on 13.12.2017 [2017/50] | Applicant(s) | For all designated states Genzyme Corporation 500 Kendall Street Cambridge, MA 02142 / US | [2013/47] | Inventor(s) | 01 /
Bailleul, Francois 46 Ile Fanac 94340, Joinville Le Pont / FR | [2014/16] |
| Former [2013/47] | 01 /
Bailleul, Francois 116 rue D'assas F-75006 Paris / FR | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2015/10] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham, NG1 5GG / GB | ||
| Former [2013/47] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 13180465.0 | 20.12.2005 | [2013/47] | Priority number, date | US20040640749P | 30.12.2004 Original published format: US 640749 P | [2013/47] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2664334 | Date: | 20.11.2013 | Language: | EN | [2013/47] | Type: | B1 Patent specification | No.: | EP2664334 | Date: | 04.03.2015 | Language: | EN | [2015/10] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 17.10.2013 | Classification | IPC: | A61K31/728, A61P19/02 | [2013/47] | CPC: |
A61K31/728 (EP,KR,US);
A61K9/0024 (EP,US);
A61P19/00 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P23/00 (EP);
A61P25/00 (EP);
A61P25/04 (EP);
A61P29/00 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2013/47] | Title | German: | Therapien zur intraartikulären Viskosupplementation | [2013/47] | English: | Regimens for intra-articular viscosupplementation | [2013/47] | French: | Schémas posologiques pour viscosupplémentation intra-articulaire | [2013/47] | Examination procedure | 02.05.2014 | Amendment by applicant (claims and/or description) | 15.05.2014 | Examination requested [2014/26] | 11.09.2014 | Communication of intention to grant the patent | 06.01.2015 | Fee for grant paid | 06.01.2015 | Fee for publishing/printing paid | 06.01.2015 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP05855034.4 / EP1835923 | Opposition(s) | Opponent(s) | 01
03.12.2015
ADMISSIBLE Generics [UK] Limited Albany Gate Darkes Lane Potters Bar Hertfordshire EN6 1AG / GB Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Patents Department 3-4 Holborn Circus London EC1N 2HA / GB | [2016/02] | 04.02.2016 | Invitation to proprietor to file observations on the notice of opposition | 28.07.2016 | Reply of patent proprietor to notice(s) of opposition | 29.03.2017 | Legal effect of rejection of opposition [2017/50] | 29.03.2017 | Date of oral proceedings | 26.07.2017 | Despatch of minutes of oral proceedings | 26.07.2017 | Date of despatch of rejection of opposition | Fees paid | Renewal fee | 14.08.2013 | Renewal fee patent year 03 | 14.08.2013 | Renewal fee patent year 04 | 14.08.2013 | Renewal fee patent year 05 | 14.08.2013 | Renewal fee patent year 06 | 14.08.2013 | Renewal fee patent year 07 | 14.08.2013 | Renewal fee patent year 08 | 12.12.2013 | Renewal fee patent year 09 | 11.12.2014 | Renewal fee patent year 10 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] - CONROZIER THIERRY ET AL, "Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis.", JOINT, BONE, SPINE : REVUE DU RHUMATISME. MAR 2003, (200303), vol. 70, no. 2, ISSN 1297-319X, pages 128 - 133, XP002391067 [A] 1-11 * page 130, paragraph 3.2 * DOI: http://dx.doi.org/10.1016/S1297-319X(03)00005-8 | [A] - LUSSIER A ET AL, "VISCOSUPPLEMENTATION WITH HYLAN FOR THE TREATMENT OF OSTEOARTHRITIS: FINDINGS FROM CLINICAL PRACTICE IN CANADA", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, (19960901), vol. 23, no. 9, ISSN 0315-162X, pages 1579 - 1585, XP000617488 [A] 1-11 * Materials and Methods; page 1580, paragraph 2 * | [A] - ANONYMOUS, "SYNVISC HYLAN G-F 20 Patient Information", (20041115), INTERNET ARTICLE, URL: http://www.synvisc.com/ussyn_synvisc_pi.pdf, (20060718), XP002391070 [A] 1-11 * 15.11.2004, mentioned as revision date in the document * * paragraph: Detailed device description; page 3, column 4 * | [AD] - ALTMAN R D ET AL, "Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee", OSTEOARTHRITIS AND CARTILAGE 2004 UNITED KINGDOM, (200408), vol. 12, no. 8, ISSN 1063-4584, pages 642 - 649, XP002391068 [AD] 1-11 * paragraph "Study design"; page 643, column 2 * DOI: http://dx.doi.org/10.1016/j.joca.2004.04.010 | [A] - BRANDT K D ET AL, "Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence?", ARTHRITIS AND RHEUMATISM. JUN 2000, (200006), vol. 43, no. 6, ISSN 0004-3591, pages 1192 - 1203, XP002391069 [A] 1-11 * page 1198, paragraph 3 * * paragraph "Conclusions"; page 1201 * DOI: http://dx.doi.org/10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L | [A] - YUSTIN DANIEL ET AL, "Use of Hylan G-F 20 for viscosupplementation of the temporomandibular joint for the management of Osteoarthritis: A case report", JOURNAL OF OROFACIAL PAIN, (1995), vol. 9, no. 4, ISSN 1064-6655, pages 375 - 379, XP009173294 [A] 1-11 * the whole document * | [I] - ALBERTO MIGLIORE ET AL, "Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis", CLINICAL RHEUMATOLOGY ; JOURNAL OF THE INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY, SPRINGER-VERLAG, LO, (20041209), vol. 24, no. 3, doi:10.1007/S10067-004-1009-1, ISSN 1434-9949, pages 285 - 289, XP019381606 [I] 1-3,5 * the whole document * DOI: http://dx.doi.org/10.1007/s10067-004-1009-1 | by applicant | US4713448 | US5099013 | US5143724 | US5399351 | US5827937 | US6521223 | - BJELLE, SCAND. J. RHEUMATOL, (1982), vol. 43, pages 35 - 48 | - REGINSTER, RHEUMATOLOGY, (2002), vol. 41, no. 1, pages 3 - 6 | - BALAZS ET AL., J. RHEUMATOL, (1993), vol. 39, pages 3 - 9 | - BALAZS ET AL., J. RHEUMATOL., (1993), vol. 39, pages 3 - 9 | - WOBIG, CLIN. THER., (1998), vol. 20, no. 3, pages 410 - 423 | - ADAMS ET AL., OSTEOARTHRITIS AND CARTILAGE, (1995), vol. 3, pages 213 - 225 | - PEYRON, J. RHEUMATOL., (1993), vol. 20, no. 39, pages 10 - 15 | - SCALE ET AL., CURR. THER. RES., (1994), vol. 55, no. 3, pages 220 - 232 | - ALTMAN ET AL., OSTEOARTHRITIS AND CART., (2004), vol. 12, pages 642 - 649 | - SCHULZ AND GLASS,, Polymers as Rheology Modifiers, ACS SYMPOSIUM SERIES, (1991), page 462 | - ALTMAN ET AL., OSTEOARTH. CART., (1996), vol. 4, pages 217 - 243 | - FRIES ET AL., ARTHRITIS RHEUMATOL., (1980), vol. 23, pages 137 - 145 | - MEENAN ET AL., ARTHRITIS RHEUMATOL., (1980), vol. 23, pages 146 - 154 | - BELLAMY ET AL., J. RHEUMATOL., (1988), vol. 34, pages 1833 - 1840 | - LEQUESNE ET AL., SCAND. J. RHEUMATOL., (1987), vol. 65, pages 85 - 89 | - THEILER ET AL., OSTEOARTH. CART., (1994), vol. 2, pages 1 - 24 | - REJESKI ET AL., OSTEOARTH. CART., (1995), vol. 3, pages 157 - 168 | - COONEY ET AL., BIOTECHNOL. PROG., (1999), vol. 15, pages 898 - 910 | - BELLAMY ET AL., J. RHEUMATOL., (1988), vol. 15, no. 12, pages 1833 - 40 | - DISCHE ET AL., J. BIOL. CHEM., (1947), vol. 167, pages 189 - 198 | - BALAZS ET AL., ANAL. BIOCHEM., (1965), vol. 12, pages 547 - 558 | US20030533429 | Opposition | US5143724 | US6096728 | US6635267 | - ROSE R J, "The intra-articular use of sodium hyaluronate for the treatment of osteo-arthrosis in the horse", NEW ZEALAND VETERINARY JOURNAL, XP003028261 | - WOBIG M; ET AL, "The Role of Elastoviscosity in the Efficacy of Viscosupplementation for Osteoarthritis of the Knee: A Comparison of Hylan G-F 20 and a Lower-Molecular Weight Hyaluronan", CLINICAL THERAPEUTICS, (19990000), vol. 21, no. 9, pages 10549 - 1562, XP002419559 DOI: http://dx.doi.org/10.1016/S0149-2918(00)80010-7 | - Altman et al, "Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee", OSTEOARTHRITIS AND CARTILAGE,, (20040801), vol. 12, no. 8, pages 642 - 649, XP002391068 DOI: http://dx.doi.org/10.1016/j.joca.2004.04.010 | - CLINICAL PHARMACOKINETICS, "Elimination of stabilised hyaluronan fro the knee joint in healthy men", Lindquist, pages 603 - 613, XP003028271 | - Hempfling, "Long-term outcome of synovial fluid substitution with Viscoseal(R) post-arthroscopy", OSTEOARTHRITIS AND CARTILAGE, vol. 11, page 79, XP003028253 | - "hyaluronan biomaterials medical applications", Balazs, encyclopedoc handbook of biomaterials and bioengineering part a: material volume 2, 00001995, pages 1693 - 1715, ISBN 0824795962, XP055264466 | - Al-Assaf et al, "THE APPIJCATION OF SHEAR AND EXTENSIONAL VISCOSITY MEASUREMENTS TO ASSESS THE POTENTIAL OF HYLAN JN VISCOSUPPLEMENTATION", Biorheology,, (19960000), vol. 33, no. 4-5, pages 319 - 332, XP055264498 | - adams et al, "The role of viscosupplementation with hylan G-F 20 (Synvisc®) in thetreatment of osteoarthritis of the knee: a Canadian multicenter trialcomparing hylan G-F 20- alone, hylan G-F 20 with non-steroidalanti-inflammatory drugs (NSAIDs) and NSAIDs alone", OSTEOARTHRITIS and CARTILAGE, vol. 3, pages 213 - 226, XP005101481 DOI: http://dx.doi.org/10.1016/S1063-4584(05)80013-5 | - Goorman et al, "Functional Outcome in Knee Osteoarthritis After Treatment With Hylan G-F 20: A Prospective Study", Arch Phys Med Rehabil, (20000400), vol. 81, pages 479 - 483, XP055264530 DOI: http://dx.doi.org/10.1053/mr.2000.4432 | - Helfet, "MANAGEMENT OF OSTEOARTHRITIS OF THE KNEE JOINT", pages 175 - 194, XP055264562 | - Yoshio, Et Al, "Investigation on Result of Use after Launch of ARTZ and ARTZ Dispo", jpn pharmacol ther, (19950000), vol. 23, no. 8, XP055264901 | - Peyron ET AL, "PRELIMINARY CLINICAL ASSESSMENT OF NA HYALURONATE INJECTION INTO HUMAN ARTHRITIC JOINTS", PATHALOGIE BIOLOGIE, (19741000), vol. 23, no. 8, pages 731 - 736, XP003028275 | - Brocq ET AL, "Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients", JOINT BONE SPINE, (20020100), vol. 69, pages 388 - 391, XP003028273 | - Marshall ET AL, "Intra-articular hyaluronan therapy", FOOT AND ANKLE CLINICS, (20030000), vol. 8, pages 221 - 232, XP055264622 DOI: http://dx.doi.org/10.1016/S1083-7515(03)00046-9 | - "Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative", POZO ET AL, EXPERIMENTAL BRAIN RESEARCH, SPRINGER, (19970000), pages 3 - 9, XP055264626 | - ZEIKAGAKU CORPORATION, "ARTZ DISPO Sodium Hyaluronate for Intra-articular Injection", Artz, (19950300), pages 1 - 3, XP055264632 | - Hamburger, "Intra-Articular Hyaluronans: A Review oF Product-Specific Safety Profiles", Seminars in Arthritis and Rheumatism,, (20030000), vol. 32, no. 5, pages 296 - 309, XP055264641 DOI: http://dx.doi.org/10.1053/sarh.2002.50008 | - Migliore I | - Conrozier t et al, "Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis", JOINT BONE SPINE, (20030301), vol. 70, no. 2, pages 128 - 133, XP002391067 DOI: http://dx.doi.org/10.1016/S1297-319X(03)00005-8 | - LUSSIER A; ET AL, "VISCOSUPPLEMENTATION WITH HYLAN FOR THE TREATMENT OF OSTEOARTHRITIS: FINDINGS FROM CLINICAL PRACTICE IN CANADa", JOURNAL OF RHEUMATOLOGY, (19960901), vol. 23, no. 9, pages 1579 - 1585, XP000617488 | - "SYNVISC HYLAN G-F 20 Patient Information", Synvisc.com, (20041115), URL: http://www.synvisc.com/ussyn_synvisc_pi.pdf, XP002391070 | - Brandt et al, "Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence?", Arthritis & Rheumatism, (20000601), vol. 43, no. 6, pages 1192 - 1203, XP002391069 DOI: http://dx.doi.org/10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L | - Phillips, "Clinical trial comparison of intra-articular sodium hyaluronate products in the horse", JOURNAL OF EQUINE VETERINARY SCIENCE,, (19890100), vol. 9, no. 1, pages 39 - 40, XP003028258 | - Rose r.j, "The intra-articular use of sodium hyaluronate for the treatment of osteo-arthrosis in the horse", NEW ZEALAND VETERINARY JOURNAL, (19790000), vol. 27, pages 5 - 8, XP003028261 | - Asheim a et al, "Intra-articular treatment of arthritis in race-horses with sodium hyaluronate", ACTA VETERINARIA SCANDINAVICA, (19790000), vol. 17, pages 379 - 394, XP003028263 | - Carrabba m. et al, "The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion ffusion", European Journal of Rheumatology & Inflammation,, (19950000), vol. 15, no. 1, pages 1 - 7, XP003028264 | - Q-MED, "Q-MED's product for the treatment of osteoarthritis in the knee approved in Europe", PRESS RELEASE, (20010508), pages 1 - 2, XP003028266 | - Bertolami et al, "Use of sodium hyaluronate in treating temporomandibular joint disorders: A randomized, double-blind, placebo-controlled clinical trial", Bertolami, (19930101), vol. 51, pages 232 - 242, XP003028274 | - Bobic, "Viscosuppleme~tatiorrlor the osteoarthritis Of the Knee", winter, vol. 6, no. 2, pages 1 - 5, XP055264961 | - Shiavinato et al, "Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,, (20020701), vol. 20, no. 4, pages 445 - 454, XP009097990 | - Conrozier t et al, "CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,", Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: An open-label, multicentre, pilot study, (20030101), vol. 21, pages 605 - 610, XP003030701 | - Krocker et al, "'Die einmalige intraartikuläre Injektion eines synthetischen Hyaluronsäurepräparates reduziert arthroseasoziierte Kniegelenkschmerzen'", Zeitschrift für Rheumatologie, (20060701), vol. 65, no. 4, pages 327 - 331, XP019425823 DOI: http://dx.doi.org/10.1007/s00393-006-0063-2 | - Chevalier et al, "Treatment of patients with symptomatic hip OA - A pilot study with intra-articular Hylan G-F 20 (Synvisc(R))", AMERICAN COLLEGE OF RHEUMATOLOGY. NATIONAL SCIENTIFIC MEETING,, (20001029), XP003030702 | - Raynauld et al, "A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results", Osteoarthritis and Cartilage, vol. 10, pages 506 - 517, XP055264977 DOI: http://dx.doi.org/10.1053/joca.2002.0798 | - M.J. Cooney, et al, "Structured Model-Based Analysis and Control of the Hyaluronic Acid Fermentation by Streptococcus zooepidemicus: Physiological Implications of Glucose and Complex-Nitrogen-Limited Growth", BIOTECHNOLOGY PROGRESS., (19991001), vol. 15, no. 5, pages 898 - 910, XP055265394 DOI: http://dx.doi.org/10.1021/bp990078n | - IUPAC Gold Book | - WD06/073835 | - Durolane Brochure IT | - Durolane PR | - Durolane Informatore Farma | - Durolane, Durolane package insert, pages 1 - 3, XP055265715 | - Q-Med, (20010000), XP003028266 | - NBDG's best practice | - "Durolane", Durolane Brochure EN, pages 1 - 9, XP003028265 | - Mcgrath, "A Comparison of Intra-Articular Hyaluronic Acid Competitors in the Treatment of Mild to Moderate Knee Osteoarthritis", journal of Arthritis, (20130000), pages 1 - 5, XP055265776 DOI: http://dx.doi.org/10.4172/2167-7921.1000108 | - Genzyme PR | - Coutts, ORTHOPEoics, (20040501), vol. 27, no. 5, pages 470 - 471, XP055265842 | - Baedling, "mplemen tion of new edicare practice l expense s . em to be delayed for one year", orthopedics today, (19971000), vol. 17, no. 10, pages 1 - 5, XP055265853 | - Scale, "Viscosupplementation of osteoarthritic knees with hylan: A treatment schedule study", (19940301), vol. 55, no. 3, pages 220 - 232, XP055265870 DOI: http://dx.doi.org/10.1016/S0011-393X(05)80166-3 | - Migliore et al, "Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis", Clinical Rheumatology, (20050600), vol. 24, no. 3, pages 285 - 289, XP019381606 DOI: http://dx.doi.org/10.1007/s10067-004-1009-1 | - aaos, "Definition and explanation of knee arthroscopy", (20100000), pages 1 - 5, XP003028254 | - aaos, "Def. Viscosupplements", (20110000), pages 1 - 38, XP003028256 | - "Def. Viscosupplementation", Def. Viscosupplementation, (20110000), pages 1 - 2, XP003028257 | - Brit. Nat. Formulary | - Fraser J R E et al, "The kinetics of hyaluronan in normal and acutely inflamed synovial joints: Observations with experimental arthritis in sheep", SEMINARS IN ARTHRITIS AND RHEUMATISM,, (19930600), vol. 22, no. 6, pages 9 - 17, XP027268527 | - Karlsson, "Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study", Rheumatology, (20021101), vol. 41, no. 11, pages 1240 - 1248, XP055266113 DOI: http://dx.doi.org/10.1093/rheumatology/41.11.1240 | - Waddell d et al, "An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthriti", CURRENT MEDICAL RESEARCH AND OPINION, (20030000), pages 499 - 507, XP055266119 DOI: http://dx.doi.org/10.1185/030079903125002090 | - Kuroki et al, "Mechanisms of action and potential uses of hyaluronan in dogs with osteoarthritis", javmauroki, (20021000), vol. 221, no. 7, pages 944 - 950, XP055266134 DOI: http://dx.doi.org/10.2460/javma.2002.221.944 | - Berg, "Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: A pilot study", Clinical and Experimental Rheumatology, (20040000), vol. 22, pages 300 - 306, XP055266137 | - Christian Akermark et al, "Non-Animal Stabilised Hyaluronic A~id in the Treatment of Osteoarthritis of the Knee A Tolerability Study", clin drug invest, (20020000), vol. 22, no. 3, pages 157 - 166, XP055266152 | - Hayakawa | - Gingerich d.a. et al, "Effect of exogenous hyaluronic acid on joint function in experimentally induced equine osteoarthritis: dosage titration studies", Research in Vetennary Sctence, (19810000), vol. 30, pages 192 - 197, XP055266205 | - Sanofi | - Charles Weiss, "HYALURONAN AND HYLAN IN THE TREATMENT OF OSTEOARTHRITIS", Clinical applicalions ofhyaluronan, pages 467 - 481, XP055266231 DOI: http://dx.doi.org/10.1533/9781845693121.467 | - Edsman et al, "lntra·articula.r Duration of Durolane TIVI after Single Injection into the Rabbit Knee", cartilage, (20110000), vol. 2, no. 4, pages 384 - 388, XP055266253 | - "ntra-Articular Hyaluronan Injections (e.g .. Supartz, Hyalgan, Synvisc, Synvisc-One, Euflexxa. and Orthovisc) for Osteoarthritis of the Knee", Mountain State Med. Insurance, pages 1 - 4, XP055266256 | - "SUPARTZ (sodium hyaluronate)", Insert Supartz, (20010200), pages 1 - 4, XP055266548 | - Insert Drthovisc | - Conrozier t et al, "Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study", Archives of Orthopaedic and Trauma Surgery, (20080326), vol. 129, no. 3, pages 417 - 423, XP019713444 | - Housman, "Evaluation of hylastan SGL-80 in symptomatic osteoarthritis (OA) of tha knee", 14t esSKA Congress -, page 1, XP055266587 | - "Hylastan SGL-80 label", Genzyrre ~ ~, Europa Genzyme, Gooimeer B V, (20150000), pages 1 - 2, XP055266600 | - Kirwan, "Is there a place for intra-articular hyaluronate in osteoarthritis of the knee?", KNEE ELSEVIER The Knee, vol. 8, pages 93 - 101, XP055266607 DOI: http://dx.doi.org/10.1016/S0968-0160(01)00075-8 | - Chevalier, "Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial", Annals of the rheumatic diseases,, (20100101), vol. 69, no. 1, pages 113 - 119, XP055086337 DOI: http://dx.doi.org/10.1136/ard.2008.094623 | - "FDA Summary for Synvisc-One Orthopaedic and Rehabilitation Devices Panel", FDA Executive Summary, pages 1 - 39, XP055266638 | - Zhang, "Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: A meta-analysis of randomised controlled trials", NNALS OF THE RHEUMATIC DISEASES,, (20040101), vol. 63, no. 8, pages 901 - 907, XP009103843 DOI: http://dx.doi.org/10.1136/ard.2003.018531 | - Housman et al, "Intra-articular hylastan versus steroid for knee osteoarthritis", KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, (20140701), vol. 22, no. 7, pages 1684 - 1692, XP055266649 DOI: http://dx.doi.org/10.1007/s00167-013-2438-7 | - Durolane instruction sheet | - Durolane information sheet | - Durolane - Physicians Instructions for Use | - Durolane leaflet | - ICH Guidelines |